S. Ahmad

发表

The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy

M. Donia, I. Svane, Ö. Met, 2018, Oncoimmunology.

The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy

I. Svane, H. Hasselbalch, Ö. Met, 2018, Leukemia.

Tryptophan 2,3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer

J. Becker, I. Svane, Ö. Met, 2015, Oncoimmunology.

Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV

I. Svane, Ö. Met, C. Niemann, 2022, Frontiers in Oncology.

Arginase-1 specific CD8+ T cells react toward malignant and regulatory myeloid cells

Ö. Met, P. thor Straten, E. Martinenaite, 2024, Oncoimmunology.

Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope

I. Svane, M. Andersen, S. M. Ahmad, 2019, Cancer Immunology, Immunotherapy.

Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway

I. Svane, S. K. Larsen, M. Andersen, 2014, Leukemia.

PD-L1-specific T cells

M. Hansen, M. Andersen, S. M. Ahmad, 2016, Cancer Immunology, Immunotherapy.